Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,043 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management guidelines for preventing exposure to antineoplastics.
Liu W, Wu Z, Sun T, Liang S, Zhu J, Zhai S, Therapeutic Drug Monitoring Of Chinese Pharmacological Society DO, Professional Committee Of Chinese Pharmaceutical Association HP, Society Of Chinese Medical Association O, Branch Of China International Exchange And Promotive Association For Medical And Healthcare N, Of Drug-Induced Diseases Of Chinese Pharmacology Society D. Liu W, et al. Among authors: sun t. Chin J Cancer Res. 2023 Feb 28;35(1):1-10. doi: 10.21147/j.issn.1000-9604.2023.01.01. Chin J Cancer Res. 2023. PMID: 36910857 Free PMC article. No abstract available.
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2- metastatic breast cancer.
Yuan Y, Zhang S, Wang T, Wang B, Wang S, Shi J, Sun T, Yin Y, Ouyang Q, Li J, Wen Y, Zhang L, Jiang Z. Yuan Y, et al. Among authors: sun t. Transl Breast Cancer Res. 2023 Apr 30;4:10. doi: 10.21037/tbcr-23-9. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751483 Free PMC article.
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang Q, Li W, Hu X, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Ning Z, Jiang Z. Zhang Q, et al. Among authors: sun t. Transl Breast Cancer Res. 2023 Jul 30;4:18. doi: 10.21037/tbcr-23-31. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751475 Free PMC article.
9,043 results